Pharmaceutical Review (Associate Editor) Synfini, a biosciences platform that speeds up the process by which pharmaceutical and other companies may design, synthesis, and commercialize compounds for medication development, has been spun out, according to a recent announcement from SRI International.
The technology integrates a variety of software and hardware technologies created by SRI over the course of a substantial, multi-year development effort. A computational synthetic planning tool, a high-throughput automated chemistry system, a flow chemistry hardware platform, and a neuro-symbolic AI molecular designer are all included in the suite. It also contains a hardware platform that can do multi-step synthesis with reliability.
Together, Chief Executive Officer Doug Donzelli and Vice President of Finance Elizabeth Miyagi co-founded the new company, Synfini Inc., with the goal of advancing the fields of pharmaceuticals, agrochemicals, and specialty chemicals by developing scalable operations for the quick synthesis and testing of specific molecules or molecular classes. It also includes Nathan Collins, Ph.D., and Peter Madrid, Ph.D., who, as chief strategy officer and head of the Applied Research group, respectively, of SRI’s Biosciences division and division of SRI, respectively, played key roles in the development of the Synfini suite at SRI.
When AI technology is paired with the Synfini platform, we have a huge possibility to significantly improve the pharmaceutical development process, which is just beginning to be seen as having an influence across so many industries.